Immune checkpoints are targets of immunotherapy, and researchers have found that patients with tumors co-expressing HIF-1α, a subtype of HIF, and PD-L1, an immune checkpoint, have a high risk of tumor recurrence and metastasis as well as lethality (57). Here, HIF1A is linked to neoplasm.